Physician profile
Gary Richter
NPI 1639178866
$4,574.66
in general payments reported to CMS, 2019-2025
25 companies · $886 in 2025
The $886 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $312 · 2021: $973 · 2022: $481 · 2023: $373 · 2024: $851 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,222.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $617.64 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $349.66 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.96 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $139.49 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $94.73 | 2019 | |
| Celgene Corporation | $93.14 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $90.16 | 2024-2025 | Resmetirom, Rezdiffra |
| Braintree Laboratories, INC. | $89.08 | 2019-2021 | |
| Gilead Sciences, INC. | $85.24 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $76.89 | 2019-2024 | Linzess |
| Allergan, INC. | $67.53 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $62.57 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $62.18 | 2023 | Dupixent |
| Daiichi Sankyo INC. | $45.93 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.44 | 2023-2025 | Wegovy |
| Exact Sciences Corporation | $37.62 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $30.09 | 2022 | |
| Pfizer INC. | $27.72 | 2019 | |
| Redhill Biopharma INC. | $27.21 | 2021 | |
| Alfasigma USA, INC. | $22.56 | 2020 | |
| Aimmune Therapeutics, INC. | $19.27 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $18.23 | 2019 | |
| Celltrion USA INC. | $16.52 | 2024 | Vegzelma |
| Intra-Sana Laboratories | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.